<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01164345</url>
  </required_header>
  <id_info>
    <org_study_id>SHEBA-09-7481-AN-CTIL</org_study_id>
    <nct_id>NCT01164345</nct_id>
  </id_info>
  <brief_title>Mozobil for Autologous Stem Cell Mobilization</brief_title>
  <official_title>Plerixafor (Plerixafor AMD 3100) + Recombinant Human G-CSF (rhG-CSF) for Autologous Peripheral Blood Stem Cell Transplantation (AutoSCT) in Hard to Mobilise Patients: a Phase IIB Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sheba Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sheba Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate Plerixafor (MOZOBIL) plus recombinant human G-CSF&#xD;
      (G-CSF) efficiency in mobilizing sufficient number of stem cells from Lymphoma (NHL and HL)&#xD;
      patients for autologous transplantation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mobilisation success rate</measure>
    <time_frame>4 weeks</time_frame>
    <description>Mobilisation success rate is defined as the mobilisation of a PBSC graft containing &gt;2x106 CD34+ cells/kg in ≤ 4 apheresis sessions. We will evaluate the time from chemotherapy to stem cell collection,number of collections required to reach &gt;2x106 CD34+ cells/kg, number of CD34+ cells collected and percentage of patients reaching &gt;5x10 CD34+ cells/kg in ≤ 4 apheresis sessions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>engraftment after transplantation</measure>
    <time_frame>100 days</time_frame>
    <description>speed of engraftment is determined by the time until recovery of blood counts after transplantation.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Non-Hodgkin's Lymphoma</condition>
  <condition>Hodgkin's Lymphoma</condition>
  <condition>Stem Cell Mobilization</condition>
  <condition>Autologous Stem Cell Transplantation</condition>
  <arm_group>
    <arm_group_label>MOZOBIL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>treatment with mozobil for autologous stem cell collection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Plerixafor</intervention_name>
    <description>Plerixafor (mozobil) 240 mcg/kg SC will be administered in the evening, 10 hours prior to initiation of apheresis.G-CSF will be administered in the morning at 10 mcg/kg SC for 4 days prior to apheresis.</description>
    <arm_group_label>MOZOBIL</arm_group_label>
    <other_name>Mozobil and Neupogen</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients eligible and planned for an autologous haematopoietic stem cell transplantation.&#xD;
&#xD;
        1.1 Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.&#xD;
&#xD;
        1.2 WBC count ≥2.5x109/L.&#xD;
&#xD;
        1.3 Absolute neutrophil count ≥1.5x109/L.&#xD;
&#xD;
        1.4 Platelet count ≥100x109/L&#xD;
&#xD;
        1.5 Adequate cardiac, renal, hepatic and pulmonary function sufficient to undergo apheresis&#xD;
        and transplantation.&#xD;
&#xD;
        1.6 Previously, heavily pretreated lymphoma patients or patients suspected to have a poor&#xD;
        bone marrow stem cell reserve for at least one of the following:&#xD;
&#xD;
          -  &gt;2 lines of chemotherapy.&#xD;
&#xD;
          -  Previous radiotherapy involving bone marrow&#xD;
&#xD;
          -  Prior therapy with specific stem cell toxic chemotherapeutic agents&#xD;
&#xD;
          -  Platelets count pre-mobilisation, ≤150.103 x mm3&#xD;
&#xD;
          -  Level of circulating CD34+ ≤ 20 cells/mcL prior to apheresis on the collection day&#xD;
&#xD;
          -  Patients &gt; 60 years of age&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        2.1 Lymphoma patients that did not fulfil the inclusion criteria.&#xD;
&#xD;
        2.2 History of any acute or chronic leukemia (including myelodysplastic syndrome.&#xD;
&#xD;
        2.3 Prior allogeneic or autologous transplantation.&#xD;
&#xD;
        2.4 Inability to tolerate stem cell harvest.&#xD;
&#xD;
        2.5 Peripheral venous access not possible.&#xD;
&#xD;
        2.6 Pregnant or nursing women.&#xD;
&#xD;
        2.7 Positive serology for hepatitis B or C.&#xD;
&#xD;
        2.8 Acute infection (febrile, i.e. temperature &gt; 38C) within 24 hours prior to dosing or&#xD;
        antibiotic therapy within 7 days prior to the first dose of GCSF.&#xD;
&#xD;
        2.9 HIV positive.&#xD;
&#xD;
        2.10 Left ventricular ejection fraction &lt; 50%.&#xD;
&#xD;
        2.11 DLCO &lt; 50%.&#xD;
&#xD;
        2.12 Splenectomised or splenic irradiation.&#xD;
&#xD;
        2.13 Psychiatric, addictive, or any disorder/disease which compromises ability to give&#xD;
        informed consent for participation in this study.&#xD;
&#xD;
        2.14 Treatment with other investigational drugs within 4 weeks of enrolling in this&#xD;
        protocol or currently enrolled in another investigational protocol during the mobilisation&#xD;
        phase.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arnon Nagler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chaim Sheba Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chaim Sheba Medical Center</name>
      <address>
        <city>Tel-Hashomer</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <study_first_submitted>July 12, 2010</study_first_submitted>
  <study_first_submitted_qc>July 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2010</study_first_posted>
  <last_update_submitted>December 1, 2015</last_update_submitted>
  <last_update_submitted_qc>December 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>non-Hodgkin's lymphoma</keyword>
  <keyword>Hodgkin's lymphoma</keyword>
  <keyword>stem cell mobilization</keyword>
  <keyword>autologous stem cell transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Plerixafor</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

